Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, 3-Arm, Open-Label, Phase 2a Clinical Trial to Evaluate the Safety and Efficacy of TTAC-0001, a Fully Human Monoclonal Antibody in Patients with Recurrent Glioblastoma

Next Previous
Trial Profile

A Multicenter, 3-Arm, Open-Label, Phase 2a Clinical Trial to Evaluate the Safety and Efficacy of TTAC-0001, a Fully Human Monoclonal Antibody in Patients with Recurrent Glioblastoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olinvacimab (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions; Registrational
  • Sponsors PharmAbcine

Most Recent Events

  • 19 Nov 2019 According to a PharmAbcine media release, Olinbashimap was approved as a rare disease treatment (ODD) by the US FDA and Korea Food and Drug Administration as a result of Phase 2a for patients with recurrent glioblastoma in Australia.
  • 01 Feb 2018 According to a PharmAbcine media release, final report of this trial will be available early in 2018
  • 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top